The notable amount of data showing the therapeutic benefits of peripheral administration of IL-1ra following ischemic brain injury [60] and the fact that IL-1 receptor antagonistic agents are already available in clinical use in autoimmune disorders prompts further research to explore whether IL-1β levels above a certain threshold may be a potential future therapeutic target in neonatal asphyxia. The gene discussed is IL1B; the disease is brain injury.